Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

S C Chu

Showing results (71-80 of 88) with videos related to

Pageof 9
Sort By:
Therapeutic Advances in Medical Oncology|January 8, 2025
The continually evolving landscape of novel therapies in oncogene-driven advanced non-small-cell lung cancerBarbara Melosky, Rosalyn A Juergens, Shantanu Banerji, et al.
Current Oncology (Toronto, Ont.)|December 13, 2021
Canadian Consensus Recommendations on the Management of <i>MET</i>-Altered NSCLCParneet K Cheema, Shantanu O Banerji, Normand Blais, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|July 17, 2008
A phase I and pharmacokinetic study of lapatinib in combination with letrozole in patients with advanced cancerQuincy S C Chu, Mary E Cianfrocca, Lori J Goldstein, et al.
Lung Cancer (Amsterdam, Netherlands)|September 18, 2025
Canadian Perspectives Revisited: Consensus on the management of ALK-rearranged NSCLCBarbara Melosky, Quincy S C Chu, Rosalyn A Juergens, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|September 5, 2006
Phase I and pharmacokinetic study of tasidotin hydrochloride (ILX651), a third-generation dolastatin-15 analogue, administered weekly for 3 weeks every 28 days in patients with advanced solid tumorsAlain C Mita, Lisa A Hammond, Peter L Bonate, et al.
Journal of the National Cancer Institute|January 9, 2026
Targeting common EGFR mutations in NSCLC-review of global phase III trials of third-generation inhibitorsBarbara Melosky, Rosalyn A Juergens, Quincy S C Chu, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|August 21, 2007
Phase I and pharmacokinetic study of lapatinib in combination with capecitabine in patients with advanced solid malignanciesQuincy S C Chu, Garry Schwartz, Johann de Bono, et al.
Current Oncology (Toronto, Ont.)|July 28, 2023
Canadian Consensus Recommendations on the Management of Extensive-Stage Small-Cell Lung CancerBarbara L Melosky, Natasha B Leighl, David Dawe, et al.
Nature Communications|December 20, 2014
Mutational landscape of intrahepatic cholangiocarcinomaShanshan Zou, Jiarui Li, Huabang Zhou, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|January 30, 2015
A phase II study of SB939, a novel pan-histone deacetylase inhibitor, in patients with translocation-associated recurrent/metastatic sarcomas-NCIC-CTG IND 200†Q S-C Chu, T O Nielsen, T Alcindor, et al.
Pageof 9

Showing results (71-80 of 88) with videos related to

Sort By:
Pageof 9
Therapeutic Advances in Medical Oncology|January 8, 2025
The continually evolving landscape of novel therapies in oncogene-driven advanced non-small-cell lung cancerBarbara Melosky, Rosalyn A Juergens, Shantanu Banerji, et al.
Current Oncology (Toronto, Ont.)|December 13, 2021
Canadian Consensus Recommendations on the Management of <i>MET</i>-Altered NSCLCParneet K Cheema, Shantanu O Banerji, Normand Blais, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|July 17, 2008
A phase I and pharmacokinetic study of lapatinib in combination with letrozole in patients with advanced cancerQuincy S C Chu, Mary E Cianfrocca, Lori J Goldstein, et al.
Lung Cancer (Amsterdam, Netherlands)|September 18, 2025
Canadian Perspectives Revisited: Consensus on the management of ALK-rearranged NSCLCBarbara Melosky, Quincy S C Chu, Rosalyn A Juergens, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|September 5, 2006
Phase I and pharmacokinetic study of tasidotin hydrochloride (ILX651), a third-generation dolastatin-15 analogue, administered weekly for 3 weeks every 28 days in patients with advanced solid tumorsAlain C Mita, Lisa A Hammond, Peter L Bonate, et al.
Journal of the National Cancer Institute|January 9, 2026
Targeting common EGFR mutations in NSCLC-review of global phase III trials of third-generation inhibitorsBarbara Melosky, Rosalyn A Juergens, Quincy S C Chu, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|August 21, 2007
Phase I and pharmacokinetic study of lapatinib in combination with capecitabine in patients with advanced solid malignanciesQuincy S C Chu, Garry Schwartz, Johann de Bono, et al.
Current Oncology (Toronto, Ont.)|July 28, 2023
Canadian Consensus Recommendations on the Management of Extensive-Stage Small-Cell Lung CancerBarbara L Melosky, Natasha B Leighl, David Dawe, et al.
Nature Communications|December 20, 2014
Mutational landscape of intrahepatic cholangiocarcinomaShanshan Zou, Jiarui Li, Huabang Zhou, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|January 30, 2015
A phase II study of SB939, a novel pan-histone deacetylase inhibitor, in patients with translocation-associated recurrent/metastatic sarcomas-NCIC-CTG IND 200†Q S-C Chu, T O Nielsen, T Alcindor, et al.
Pageof 9